ArticleDiabetes, obesity & metabolism2025
Minimum expectations for market authorization of continuous glucose monitoring devices in Europe-'eCGM' compliance status.
Article in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- CGM Accuracy in a Fragmented Regulatory Landscape: A Commentary on Harmonisation and Recent Evidence.Diabetes, obesity & metabolism · 2026Article
- Glycemic Instability and Skin Health: Metabolic Mechanisms Linking Dietary Patterns with Cutaneous Dysfunction.Journal of clinical medicine · 2026Review
- Trends in accuracy management of continuous glucose monitoring systems.Diabetology international · 2026Review
- Nanostructured electrode materials and flexible-substrate engineering for wearable multi-analyte biosensors in diabetes monitoring and personalized care: a comprehensive review.Journal of materials science. Materials in medicine · 2026Review
- International clinical opinion on transparency, standardisation, and calibration alignment in the performance evaluation of systems for continuous glucose monitoring.Diabetes, obesity & metabolism · 2026Review
- Discordant real-world glycaemic outcomes with Omnipod™ 5 and MiniMed™ 780G in adults with type 1 diabetes: Why validated measures matter.Diabetes, obesity & metabolism · 2026Article
- Performance of three simultaneously used rtCGM systems around a physically active weekend camp in adults with type 1 diabetes: A prospective lab and real-world study.Diabetes, obesity & metabolism · 2026Article
- Diabetes community calls for quality standards for continuous glucose monitoring devices.The Lancet regional health. Europe · 2026Article
- Performance of a New Continuous Glucose Monitoring System in German Adults Living with Diabetes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Article
- Article
- Comment to 'Minimum expectations for market authorization of continuous glucose monitoring devices in Europe-"eCGM"'.Diabetes, obesity & metabolism · 2025Article
- Continuous Glucose Monitoring in People at High Risk of Diabetes and Dysglycaemia: Transforming Early Risk Detection and Personalised Care.Life (Basel, Switzerland) · 2025Review
- Continuous glucose monitoring system in diabetes in pregnancy: a narrative review.Diabetology & metabolic syndrome · 2025Review
- Consensus statement on standardizing CGM evaluation metrics in Latin America: an expert approach.Diabetology & metabolic syndrome · 2025Article
- Minimum expectations for market authorization of continuous glucose monitoring devices in Europe-'eCGM' compliance status.Diabetes, obesity & metabolism · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.